1346. Linezolid for the Treatment of Extensively Drug Resistant Tuberculosis?multicenter, randomized controlled study
Session: Poster Abstract Session: Clinical Trials
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • Poster 1 USA.pdf (1.2 MB)
  • Background: Extensively drug-resistant tuberculosis (XDR-TB) has recently emerged as a global public health problem. To evaluate the clinical efficacy and safety of Linezolid for the treatment of  XDR-TB.

    Methods: We enrolled 59 patients who had sputum-culture-positive XDR-TB tuberculosis in 5 major tuberculosis specialized hospital in China. Patients were randomly assigned to linezolid therapy group (n=30) and control group (n=29). Patients in two groups were adopted two years of individual-based chemotherapy regimens based on the patient medication history and drug susceptibility test results. Meanwhile, linezolid therapy group was added to linezolid that started at a dose of 1200 mg per day for 4 to 6 weeks, followed by 300 to 600 mg per day for at least 6 months.

    Results: 4 Patients in linezolid therapy group discontinued therapy because of side effects or other reasons, and 3 Patients in control group discontinued therapy because of side effects or other reasons. In linezolid therapy group, the longest period of applying linezolid for treatment was up to 24 months, the minimum was 6 months with the average of about 12 months. The sputum culture conversion rates in the linezolid therapy group were 73.07% (19/26) in the 12th month after treatment, significantly higher than those of control group (30.76%, 8/26) (P <0.001). The cavity closure or reduced rates in the linezolid therapy group were 57.69% (15/26) in the 12th month after treatment, significantly higher than those of control group (26.92%, 7/26) (P <0.001). Of 20 patients completed therapy in the linezolid therapy group, 14 (70%) had treatment success (cured and treatment completion). Of 21 patients completed therapy in the control group, only 7 (30%) had treatment success. In the linezolid therapy group, 13 (50%) had adverse events such as peripheral neuropathy, leucopenia and anaemia, gastrointestinal reactions, liver injury etc. However, 10(38.46%) had adverse events in the control group.

    Conclusion: Linezolid containing chemotherapy for treatment of XDR-TB may significantly promote cavity closure, accelerate sputum culture conversion and improve treatment success rates. Meanwhile adverse reaction might be tolerated and resolve after suitable intervention.

    Shenjie Tang, Lan Yao, Xiaohui Hao, Yidian Liu, Hua Sun and Jin Gu, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

    Disclosures:

    S. Tang, None

    L. Yao, None

    X. Hao, None

    Y. Liu, None

    H. Sun, None

    J. Gu, None

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.